Open label, uncontrolled study of XRP9881 [larotaxel] in combination with trastuzumab (Herceptin) in patients with HER2 positive metastatic breast cancer (MBC).

Trial Profile

Open label, uncontrolled study of XRP9881 [larotaxel] in combination with trastuzumab (Herceptin) in patients with HER2 positive metastatic breast cancer (MBC).

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Larotaxel (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2011 Actual end date changed from Dec 2010 to Jan 2011 as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top